Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

Blood (2023) 142 (Supplement 1): 2913.

https://doi.org/10.1182/blood-2023-186620

Published: 2023

Journal Articles

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Camille Abboud, Sr., Jan Maciej Zaucha, Scott R. Solomon, Terrence Bradley, Elie Mouhayar, Noemi Angelosanto, Hendrik Nogai, Renata Dudziak, Tomasz Rzymski, Peter Littlewood, Krzysztof Brzózka, Axel Glasmacher, Gautam Borthakur, Howard A. Burris, Sr., Ewa Lech Marańda

Blood (2022) 140 (Supplement 1): 6228–6229.

https://doi.org/10.1182/blood-2022-163150

Published: 2022

Journal Articles

Incidence of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections and Use of Prophylaxis in Lenalidomide-Treated Multiple Myeloma (MM) Patients (pts): An Analysis of MM Trials

Dianna Gary, BSN, Lilia Weiss, MD, Zhinuan Yu, PhD, Qiang Xu, PhD, Neil Minton, MD, David Gillen, MD, Axel Glasmacher, MD, John Freeman, MSc, BSc, JD

Blood (2014) 124 (21): 3451.

https://doi.org/10.1182/blood.V124.21.3451.3451

Published: 2014

Journal Articles

Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study

Andrea Kuendgen, MD, Michael Lauseker, Alan F. List, MD, Pierre Fenaux, MD, PhD, Aristoteles Giagounidis, MD, Nancy Brandenburg, PhD, Jay Backstrom, MD, Axel Glasmacher, MD, Joerg Hasford, MD, Ulrich Germing, MD, On behalf of the International Working Group on MDS with del5q

Blood (2011) 118 (21): 119.

https://doi.org/10.1182/blood.V118.21.119.119

Published: 2011

Journal Articles

Comparative Effectiveness of Bisphoshonates In Multiple Myeloma

Rahul Mhaskar, MD, MPH, Jasmina Redzepovic, Keith Wheatley, Otavio Clark, Axel Glasmacher, MD, Branko Miladinovic, PhD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2010) 116 (21): 3028.

https://doi.org/10.1182/blood.V116.21.3028.3028

Published: 2010

Journal Articles

Outcome of Fungal Infection in Patients Undergoing Myelosuppressive Chemotherapy in a Tertiary Care Centre During 12 Years (1995-2006).

Marie von Lilienfeld-Toal, MD, Axel Glasmacher, MD, Günter Marklein, MD, Peter Brossart, MD, Corinna Hahn-Ast, PhD

Blood (2009) 114 (22): 1384.

https://doi.org/10.1182/blood.V114.22.1384.1384

Published: 2009

Journal Articles

Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis.

Rahul Suresh Mhaskar, MPH, Jasmina Redzepovic, PhD, Keith Wheatley, DPhil, Otavio Clark, MD, PhD, Axel Glasmacher, MD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2009) 114 (22): 3858.

https://doi.org/10.1182/blood.V114.22.3858.3858

Published: 2009

Journal Articles

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

Stefan Knop, Christian Gerecke, Peter Liebisch, Max S. Topp, Uwe Platzbecker, Orhan Sezer, Christina Vollmuth, Karina Falk, Axel Glasmacher, Uwe Maeder, Hermann Einsele, Ralf C. Bargou

Blood (2009) 113 (18): 4137–4143.

https://doi.org/10.1182/blood-2008-10-184135

Published: 2009

Journal Articles

Long-Term Disease Control in Patients with Primary Central Nervous System Lymphoma

Blood (2008) 112 (11): 3600.

https://doi.org/10.1182/blood.V112.11.3600.3600

Published: 2008

Journal Articles

Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).

Ambuj Kumar, MD, MPH, Mohamed A. Kharfan-Dabaja, MD, Axel Glasmacher, MD, Benjamin Djulbegovic, MD, PhD

Blood (2007) 110 (11): 936.

https://doi.org/10.1182/blood.V110.11.936.936

Published: 2007

Journal Articles

Early Relapses in Primary CNS Lymphoma (PCNSL) without Intraventricular Treatment.

Ingo G.H. Schmidt-Wolf, MD, Hendrick Pels, MD, Annika Jurgens, MD, Axel Glasmacher, MD, Holger Schulz, MD, Andreas Engert, MD, Michael Linnebank, MD, Gabriele Schackert, MD, Heinz Reichmann, MD, Frank Kroschinsky, MD, Marlies Vogt-Schaden, MD, Gertlinde Egerer, MD, Carlo Schaller, MD, Monika Lamprecht, MD, Ulrich Bogdahn, MD, Martina Deckert, MD, Rolf Fimmers, MD, Christoph Bangard, MD, Uwe Schlegel, MD

Blood (2007) 110 (11): 4440.

https://doi.org/10.1182/blood.V110.11.4440.4440

Published: 2007

Journal Articles

Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.

Blood (2007) 110 (11): 2725.

https://doi.org/10.1182/blood.V110.11.2725.2725

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

Journal Articles

Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.

Ingo G.H. Schmidt-Wolf, MD, Hendrik Pels, MD, Annika Juergens, MD, Axel Glasmacher, MD, Holger Schulz, MD, Frank Kroschinsky, MD, Gertlinde Egerer, MD, Monika Lamprecht, MD, Caecilia Wismeth, MD, Uwe Schlegel, MD

Blood (2006) 108 (11): 2452.

https://doi.org/10.1182/blood.V108.11.2452.2452

Published: 2006

Journal Articles

Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.

Ingo G.H. Schmidt-Wolf, MD, Annika Juergens, MD, Hendrik Pels, MD, Axel Glasmacher, MD, Holger Schulz, MD, Andreas Engert, MD, Michael Linnebank, MD, Heinz Reichmann, MD, Frank Kroschinsky, MD, Marlies Vogt-Schaden, MD, Gerlinde Egerer, MD, Klaus Fliessbach, MD, Uwe Schlegel, MD

Blood (2006) 108 (11): 2453.

https://doi.org/10.1182/blood.V108.11.2453.2453

Published: 2006

Journal Articles

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Blood (2005) 106 (11): 424.

https://doi.org/10.1182/blood.V106.11.424.424

Published: 2005

Journal Articles

Itraconazole for Antifungal Prophylaxis in Neutropenic Patients: An Update of a Meta-Analysis with Now 3846 Patients.

Axel Glasmacher, MD, Corinna Hahn, PhD, Marie von Lilienfeld-Toal, MD, Katjana Orlopp, MD, Ingo Schmidt-Wolf, MD, Archie Prentice, MD

Blood (2005) 106 (11): 3224.

https://doi.org/10.1182/blood.V106.11.3224.3224

Published: 2005

Journal Articles

Cost-Effectiveness of Itraconazole for the Prophylaxis of Invasive Fungal Infections for Neutropenic Patients; a Study for 3 European Countries.

Maarten J. Postma, PhD, Robin de Vries, MSc, Harriet Christopherson, MSc, Sarah Howells, MSc, Keith Tolley, MSc, Simon Daenen, MD, Axel Glasmacher, MD, Archibald Prentice, MD, Angela Christie

Blood (2005) 106 (11): 3133.

https://doi.org/10.1182/blood.V106.11.3133.3133

Published: 2005

NARROW

Safety and Efficacy Results from CLI120-001 a Phase 1 Study in RR-AML and HR-MDS: Update from Higher Dose Levels

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Incidence of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections and Use of Prophylaxis in Lenalidomide-Treated Multiple Myeloma (MM) Patients (pts): An Analysis of MM Trials

Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study

Comparative Effectiveness of Bisphoshonates In Multiple Myeloma

Outcome of Fungal Infection in Patients Undergoing Myelosuppressive Chemotherapy in a Tertiary Care Centre During 12 Years (1995-2006).

OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma.

Bisphosphonates in Multiple Myeloma. A Systematic Review and Meta Analysis.

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

Long-Term Disease Control in Patients with Primary Central Nervous System Lymphoma

Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).

Early Relapses in Primary CNS Lymphoma (PCNSL) without Intraventricular Treatment.

Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.

Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Itraconazole for Antifungal Prophylaxis in Neutropenic Patients: An Update of a Meta-Analysis with Now 3846 Patients.

Cost-Effectiveness of Itraconazole for the Prophylaxis of Invasive Fungal Infections for Neutropenic Patients; a Study for 3 European Countries.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only